Analysts’ Weekly Ratings Changes for Adicet Bio (ACET)

Adicet Bio (NASDAQ: ACET) has recently received a number of price target changes and ratings updates:

• 9/20/2024 – Adicet Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
• 9/19/2024 – Adicet Bio had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 9/11/2024 – Adicet Bio was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating.
• 9/11/2024 – Adicet Bio had its price target lowered by analysts at Canaccord Genuity Group Inc. from $19.00 to $8.00. They now have a “buy” rating on the stock.
• 9/10/2024 – Adicet Bio was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 9/10/2024 – Adicet Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
• 8/30/2024 – Adicet Bio was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/22/2024 – Adicet Bio was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 8/14/2024 – Adicet Bio was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 8/14/2024 – Adicet Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 8/14/2024 – Adicet Bio had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $19.00 price target on the stock.
• 8/13/2024 – Adicet Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.

Adicet Bio Stock Down 6.5 %

Shares of ACET stock opened at $1.43 on Tuesday. The stock has a fifty day moving average of $1.44 and a 200 day moving average of $1.61. The firm has a market capitalization of $117.51 million, a price-to-earnings ratio of -0.48 and a beta of 1.79. Adicet Bio, Inc. has a 52 week low of $1.05 and a 52 week high of $3.77.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.03. Equities research analysts anticipate that Adicet Bio, Inc. will post -1.35 earnings per share for the current year.

Institutional Trading of Adicet Bio

A number of hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. purchased a new position in Adicet Bio during the 1st quarter valued at about $28,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Adicet Bio in the 1st quarter worth approximately $37,000. Point72 DIFC Ltd grew its stake in shares of Adicet Bio by 77.5% in the 2nd quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock worth $40,000 after buying an additional 14,596 shares during the last quarter. Marshall Wace LLP bought a new position in Adicet Bio during the 2nd quarter valued at approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Adicet Bio during the second quarter valued at $62,000. Institutional investors own 83.89% of the company’s stock.

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.